PMC:7228307 / 3065-3309 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T14","span":{"begin":224,"end":233},"obj":"Body_part"}],"attributes":[{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"with over 100 mAbs approved for clinical use or in late‐stage clinical trials and over 600 in various stages of clinical development.1\nThe therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimm"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T14","span":{"begin":224,"end":233},"obj":"Body_part"}],"attributes":[{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"with over 100 mAbs approved for clinical use or in late‐stage clinical trials and over 600 in various stages of clinical development.1\nThe therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimm"}